shareholders’ equity increased. As of 31 March 2019, the Company had Debt to Equity ratio equal to 0.09:1 times, decreased from 31 December 2018 which was equal to 0.13:1 times, indicating lessen liabilities
31st March, 2019 which was reviewed by authorized Auditor with the details as follows: The total revenues of the Company and its Subsidiaries in the Quarter 1/2019 was equal to 77.89 million Baht, a
/2019 as at 31st March, 2019 which was reviewed by authorized Auditor with the details as follows: The total revenues of the Company and its Subsidiaries in the Quarter 1/2019 was equal to 77.89 million
2019 equal to 170.9 million baht or 40.2% due to The increase in profit from loans from the purchase of receivables (Income from non- performing loans that have been fully amortized the investment value
% and It net loss equal 3.46% for total revenue. 2. The Company Financial Statement (9 month) TCJ had total revenue of Baht 274.09 million compared with Baht 292.05 million in the same period of last year
, fairness and equal competition, and ensuring that the issuance or amendment to the criteria applicable to the members must be proceeded by considering opinions of stakeholders and obtaining approval from
amount of 33,339,500 baht for using inside information to purchase shares of Siam Makro Public Company Limited (MAKRO), and (5) Somsak Chiarawisithkul and (6) Areeya Asvanund at a separate, equal amount of
DOD BIOTECH PUBLIC COMPANY LIMITED 111 Moo 2 TambonThachin, Amphurmuangsamutsakhon, Samutsakhon 74000 Page 1 of 3 No. DOD026/2563 February 26, 2020 Subject Management Discussion and Analysis of for
DOD BIOTECH PUBLIC COMPANY LIMITED 111 Moo 2 TambonThachin, Amphurmuangsamutsakhon, Samutsakhon 74000 Page 1 (Translate) NO. DOD 030/2019 August 13, 2019 Subject: Clarification of the operating
DOD BIOTECH PUBLIC COMPANY LIMITED 111 Moo 2 TambonThachin, Amphurmuangsamutsakhon, Samutsakhon 74000 Page 1 (Translate) NO. DOD 035/2019 November 11, 2019 Subject: Clarification of the operating